Natriuretic peptides and remodeling in heart failure.
Burnett
John C
JC
Mayo Clinic College of Medicine, Rochester, MN 55905, USA. burnett.john@mayo.edu
D000450:Aldosterone / Q000378:metabolism; D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004719:Endomyocardial Fibrosis / Q000188:drug therapy / Q000209:etiology; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000378:metabolism / Q000627:therapeutic use; D045265:Natriuretic Peptides / Q000378:metabolism / Q000627:therapeutic use*; D012964:Sodium / Q000378:metabolism; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000187:drug effects*
D002316:Cardiotonic Agents; D045265:Natriuretic Peptides; D020097:Natriuretic Peptide, Brain; D000450:Aldosterone; D012964:Sodium